Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/neuros/nyx183 | DOI Listing |
Indian J Med Ethics
January 2025
IMU Centre for Education, IMU University, Kuala Lumpur, MALAYSIA.
I read with great interest the editorial on the pharmaceutical company-healthcare relationship published in the April-June issue of this journal [1]. Clinical practice guidelines are increasingly used by physicians to guide treatment decisions, and the pharmaceutical industry focuses on influencing the authors of these guidelines. Almost one in four guideline writers with no disclosed ties may have potentially relevant undisclosed ties to pharmaceutical companies [2].
View Article and Find Full Text PDFAesthetic Plast Surg
January 2025
University of Passo Fundo, Passo Fundo, RS, Brazil.
Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.
View Article and Find Full Text PDFJ Neurol
January 2025
Department of Neurology, Dizziness Center, and Clinical Neuroscience Center, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.
BMC Pregnancy Childbirth
January 2025
School of Public Health, College of Medicine and Health Sciences, Wachemo University, Hossana, Ethiopia.
Background: High-risk fertility behavior (HRFB) is a serious public health issue that may influence the country's economic development as well as the health status of mothers mainly in developing countries, like Ethiopia.However, there is a scarcity of evidence about HRFB and associated factors in the study area. Therefore, this study assessed HRFB and associated factors among mothers attending antenatal care in public health facilities in Hossana town, Hadiya zone, Central Ethiopia Region.
View Article and Find Full Text PDFBMJ Open
December 2024
Department of Medicine, The University of Chicago, Chicago, Illinois, USA.
Objective: The COVID-19 pandemic required the rapid and often widespread implementation of medical practices without robust data. Many of these practices have since been tested in large, randomised trials and were found to be in error. We sought to identify incorrect recommendations, or reversals, among National Institute of Health COVID-19 guidelines and Food and Drug Administration (FDA) approvals and authorisations.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!